Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Haffner

Showing results (131-140 of 169) with videos related to

Pageof 17
Sort By:
JCI Insight|March 16, 2021
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancerW Nathaniel Brennen, Yezi Zhu, Ilsa M Coleman, et al.
Nature Cell Biology|August 17, 2023
KDM6A epigenetically regulates subtype plasticity in small cell lung cancerLeslie Duplaquet, Yixiang Li, Matthew A Booker, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
OGDHL regulates nucleotide metabolism, tumor growth, and neuroendocrine marker expression in prostate cancerMatthew J Bernard, Angel Ruiz, Johnny A Diaz, et al.
The Journal of Clinical Investigation|June 15, 2021
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growthMichael D Nyquist, Lisa S Ang, Alexandra Corella, et al.
Nature Communications|April 11, 2023
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapyVipul Bhatia, Nikhil V Kamat, Tiffany E Pariva, et al.
Nature Cancer|February 5, 2022
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progressionZoila A Lopez-Bujanda, Michael C Haffner, Matthew G Chaimowitz, et al.
The Journal of Clinical Investigation|May 17, 2021
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growthMichael D Nyquist, Lisa S Ang, Alexandra Corella, et al.
Science Translational Medicine|August 2, 2023
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancersAlvaro Quintanal-Villalonga, Vidushi Durani, Amin Sabet, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Deep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncologyRobert D Patton, Alexander Netzley, Thomas W Persse, et al.
Cancer Biology & Therapy|September 7, 2010
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinomaAlvarez Hector, Elizabeth A Montgomery, Collins Karikari, et al.
Pageof 17

Showing results (131-140 of 169) with videos related to

Sort By:
Pageof 17
JCI Insight|March 16, 2021
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancerW Nathaniel Brennen, Yezi Zhu, Ilsa M Coleman, et al.
Nature Cell Biology|August 17, 2023
KDM6A epigenetically regulates subtype plasticity in small cell lung cancerLeslie Duplaquet, Yixiang Li, Matthew A Booker, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
OGDHL regulates nucleotide metabolism, tumor growth, and neuroendocrine marker expression in prostate cancerMatthew J Bernard, Angel Ruiz, Johnny A Diaz, et al.
The Journal of Clinical Investigation|June 15, 2021
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growthMichael D Nyquist, Lisa S Ang, Alexandra Corella, et al.
Nature Communications|April 11, 2023
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapyVipul Bhatia, Nikhil V Kamat, Tiffany E Pariva, et al.
Nature Cancer|February 5, 2022
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progressionZoila A Lopez-Bujanda, Michael C Haffner, Matthew G Chaimowitz, et al.
The Journal of Clinical Investigation|May 17, 2021
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growthMichael D Nyquist, Lisa S Ang, Alexandra Corella, et al.
Science Translational Medicine|August 2, 2023
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancersAlvaro Quintanal-Villalonga, Vidushi Durani, Amin Sabet, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Deep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncologyRobert D Patton, Alexander Netzley, Thomas W Persse, et al.
Cancer Biology & Therapy|September 7, 2010
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinomaAlvarez Hector, Elizabeth A Montgomery, Collins Karikari, et al.
Pageof 17